2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

4:30PM-6:00PM: Abstract Number: 2L

Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study

ACR Late-breaking Abstract Session

4:30PM-6:00PM: Abstract Number: 3215

Bim Suppresses the Development of SLE By Limiting Macrophage Inflammatory Responses

Systemic Lupus Erythematosus - Animal Models

4:30PM-6:00PM: Abstract Number: 3155

Bob1 Expression Is Elevated in Rheumatoid Synovium and Its Expression in B Cells Is Required for Development of Collagen-Induced Arthritis

B cell Biology and Targets in Autoimmune Disease: Novel B cell roles in RA and SLE

4:30PM-6:00PM: Abstract Number: 3164

Calcium Pyrophosphate Deposition Disease and Associated Medical Co-Morbidities in the Veteran Population

Metabolic and Crystal Arthropathies II: Mechanisms and Associations

4:30PM-6:00PM: Abstract Number: 3200

Characterization of Early and Progressive Autoimmunity in Sjogrens Syndrome: The Incomplete Sjogrens Syndrome Model

Sjögren's Syndrome II: Clinical Discoveries

4:30PM-6:00PM: Abstract Number: 3212

Characterizing the Effects of the G-CSF-R Coding rs13377964 SNP Located within Murine Lupus Susceptibility Locus Sle2c2

Systemic Lupus Erythematosus - Animal Models

4:30PM-6:00PM: Abstract Number: 3195

Circulating Micro-RNA Profiles in Responders to Adalimumab Plus Methotrexate Versus Methotrexate Alone: A Placebo-Controlled Clinical Trial

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy VI: Strategies

4:30PM-6:00PM: Abstract Number: 3197

Clinical Practice Experience in Rheumatoid Arthritis Patients Treated with Triple Therapy and Methotrexate-Tumor Necrosis Factor Inhibition Differs from That of Randomized Controlled Trials

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy VI: Strategies

4:30PM-6:00PM: Abstract Number: 3171

Combination Therapy with Denosumab and Biologic DMARD Associated with Higher Risk of Serious Infections Compared to Denosumab Alone and Biologic DMARD Alone

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis

4:30PM-6:00PM: Abstract Number: 3160

Comparative Rates of Serious Infections and All-Cause Mortality Among Systemic Lupus Erythematosus Patients Receiving Mycophenolate Mofetil Versus Azathioprine

Epidemiology and Public Health IV: Risk Factors and Comorbidities for SLE and Psoriatic Arthritis

4:30PM-6:00PM: Abstract Number: 3211

Current Smoking, Its Intensity and Duration, Is Associated with Fat Metaplasia on MRI in Patients with Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects, Imaging and Biomarkers

4:30PM-6:00PM: Abstract Number: 3179

Diagnosing Childhood Small Vessel CNS Vasculitis

Pediatric Rheumatology - Clinical and Therapeutic Aspects IV: Imaging and Novel Clinical Interventions

4:30PM-6:00PM: Abstract Number: 3169

Diagnostic Value of Ultrasound for the Diagnosis of Gout in a Prospective Cross-Sectional Study

Metabolic and Crystal Arthropathies II: Mechanisms and Associations

4:30PM-6:00PM: Abstract Number: 3165

Do Omega-3 Fatty Acids Reduce Risk of Recurrent Gout Attacks?

Metabolic and Crystal Arthropathies II: Mechanisms and Associations

4:30PM-6:00PM: Abstract Number: 3172

Effect of Anti Citrullinated Protein Antibodies on Periarticular and Systemic Bone Mass in Early Arthritis Patients

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].